Showing results (191-200 of 297) with videos related to
Sort By:
Pageof 30
Clinical Pharmacology and Therapeutics|November 9, 2018
Essential Characteristics of Pharmacogenomics Study PublicationsCaroline F Thorn, Michelle Whirl-Carrillo, Houda Hachad, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.Clinical Pharmacology and Therapeutics|June 18, 2003
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphineMichael B Sawyer, Federico Innocenti, Soma Das, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2004
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanFederico Innocenti, Samir D Undevia, Lalitha Iyer, et al.British Journal of Clinical Pharmacology|December 24, 2010
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozoleLandry K Kamdem, Yong Liu, Vered Stearns, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I studyCharles M Rudin, John L Marshall, Chao Hui Huang, et al.Cancer Chemotherapy and Pharmacology|August 5, 2008
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compoundsFederico Innocenti, Snezana Mirkov, Ramamoorthy Nagasubramanian, et al.Ejhaem|June 16, 2025
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax TherapyRafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, et al.The Pharmacogenomics Journal|September 12, 2019
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementationWenndy Hernandez, Keith Danahey, Xun Pei, et al.Investigational New Drugs|January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week scheduleAntonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.Pageof 30